They treated small (200 μm) or large (400 μm) spheroids composed of HER2-positive human BC cells in vitro with trastuzumab-modified pH-responsive [225Ac]Ac-DOTA-liposomes or non-pH responsive [225Ac]Ac-DOTA-liposomes. The gene discussed is ERBB2; the disease is breast cancer.